Allogeneic stem cell transplantation for chronic myeloid leukemia in the tyrosine kinase inhibitor era

The Egyptian Journal of Haematology

article

AhmadAlshomar¹ 

[1] Department of Medicine, College of Medicine, Qassim University

关键词: allogeneic stem cell transplant;    bone marrow transplant;    chronic myeloid leukemia;    CML;    hematopoietic stem cell transplantation;    HSCT;    TKI;    tyrosine kinase inhibitors;   

DOI  :  10.4103/ejh.ejh_4_22

来源: Medknow

【 摘 要 】

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm characterized by the production of mature granulocytes and their precursors that are dysregulated and uncontrolled. The presence of the Philadelphia chromosome (Ph) is the hallmark of CML; it encodes a chimeric protein with constitutive tyrosine kinase activity that leads to uncontrolled cell growth and eventually the development of CML. Tyrosine kinase inhibitors (TKI) revolutionized the management of patients with CML. Before TKIs, hematopoietic stem cell transplantation had a major role in the treatment of these patients, but currently, its use is limited to cases presenting in the advanced phase and patients in the chronic phase failing multiple TKIs. In this article, the author summarizes the data about hematopoietic stem cell transplantation use in chronic phase CML, reviews the published guidelines, and provides his opinion.

【 授权许可】

Unknown